tradingkey.logo

Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

ReutersFeb 6, 2026 1:25 PM

Shares of  drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket

 Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders

CNMD's shares were up 20% at $1.7 premarket

CNMD's  MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co

 Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery

PLRZ shares down over 99%, CNMD down ~41% in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI